shutterstock_621316742_tero_vesalainen

Tero Vesalainen / Shutterstock.com

20 September 2022AmericasStaff Writer

‘Pervasive abuse’ of patent system at root of drug pricing crisis: I-MAK

Report found that four times as many patents are granted on the top ten drugs in the US, compared to Europe | Non-profit says that the US’ patent system is ‘broken’.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

I-MAK: saving lives by curing the patent system

19 October 2018 Non-profit organisation I-MAK is waging a global challenge against what it sees as invalid pharmaceutical patents, with access to life-saving drugs its main priority. LSIPR speaks to co-founder Tahir Amin to find out more.

Patent abuse driving high drug prices, non-profit claims

2 August 2018 Aggressive and exploitative patenting strategies are enabling drug makers to regularly increase prices in the US and extend monopolies, according to a new report from non-profit group the Initiative for Medicines, Access and Knowledge.

More on this story

I-MAK: saving lives by curing the patent system

19 October 2018 Non-profit organisation I-MAK is waging a global challenge against what it sees as invalid pharmaceutical patents, with access to life-saving drugs its main priority. LSIPR speaks to co-founder Tahir Amin to find out more.

Patent abuse driving high drug prices, non-profit claims

2 August 2018 Aggressive and exploitative patenting strategies are enabling drug makers to regularly increase prices in the US and extend monopolies, according to a new report from non-profit group the Initiative for Medicines, Access and Knowledge.

More on this story

I-MAK: saving lives by curing the patent system

19 October 2018 Non-profit organisation I-MAK is waging a global challenge against what it sees as invalid pharmaceutical patents, with access to life-saving drugs its main priority. LSIPR speaks to co-founder Tahir Amin to find out more.

Patent abuse driving high drug prices, non-profit claims

2 August 2018 Aggressive and exploitative patenting strategies are enabling drug makers to regularly increase prices in the US and extend monopolies, according to a new report from non-profit group the Initiative for Medicines, Access and Knowledge.

More features

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

Teva fights for re-listing of inhaler patents at US appeals court

CRISPR patents revoked following Nobel Prize winners’ withdrawal

White & Case hires experienced litigator from A&O Shearman

President Trump 2.0: Five major areas to watch